Our group has evaluated the implications of MAP3K7 and CHD1 co-loss on the AR axis and have found that PCa cells with this subtype exhibit increased AR activity, resistance to enzalutamide, and increased AR splice variant levels. The gene discussed is CHD1; the disease is posterior cortical atrophy.